NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Metrics to compare | NRSN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNRSNPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.1x | −1.8x | −0.5x | |
PEG Ratio | −0.12 | −0.02 | 0.00 | |
Price/Book | 12.2x | 1.7x | 2.6x | |
Price / LTM Sales | - | 38.3x | 2.9x | |
Upside (Analyst Target) | - | 520.2% | 45.8% | |
Fair Value Upside | Unlock | 14.5% | 8.6% | Unlock |